Heart rate variability analysis in postherpetic neuralgia patients undergoing pulsed radiofrequency nerve root block: before and after treatment - PHNP study

Start Date05 Feb 2024

Sponsor / Collaborator

Kindai University Faculty of Medicine

JPRN-UMIN000054809

/ RecruitingNot ApplicableIIT

Non-invasive identification of high-risk plaques in non-culprit lesions of acute coronary syndrome - Non-invasive identification of high-risk plaques in non-culprit lesions of acute coronary syndrome

Start Date01 Dec 2023

Sponsor / Collaborator

Kindai University Faculty of Medicine

100 Clinical Results associated with Kindai University Faculty of Medicine

0 Patents (Medical) associated with Kindai University Faculty of Medicine

2,970

Literatures (Medical) associated with Kindai University Faculty of Medicine

01 Mar 2025·European Journal of Cell Biology

Cholangiocyte organoids for disease, cancer, and regenerative medicine

Article

Author: Kawai, Munenori ; Nakayama, Shinnosuke ; Namikawa, Mio ; Fukuda, Akihisa ; Muta, Yu ; Yamakawa, Go ; Masuda, Tomonori ; Omatsu, Mayuki ; Mizukoshi, Kenta ; Seno, Hiroshi ; Tsuruyama, Tatsuaki ; Kashima, Hirotaka ; Nakanishi, Yuki ; Maruno, Takahisa ; Hiramatsu, Yukiko ; Nagao, Munemasa ; Matsuyama, Sho ; Iimori, Kei

The biliary tract is a ductal network comprising the intrahepatic (IHBDs) and extrahepatic bile duct (EHBDs). Biliary duct disorders include cholangitis, neoplasms, and injury. However, the underlying mechanisms are not fully understood. With advancements in 3D culture technology, cholangiocyte organoids (COs) derived from primary tissues or induced pluripotent stem cells (iPSCs) can accurately replicate the structural and functional properties of biliary tissues. These organoids have become powerful tools for studying the pathogenesis of biliary diseases, such as cystic fibrosis and primary sclerosing cholangitis, and for developing new therapeutic strategies for cholangiocarcinoma. Additionally, COs have the potential to repair bile duct injuries and facilitate transplantation therapies. This review also discusses the use of organoids in genetically engineered mouse models to provide mechanistic insights into tumorigenesis and cancer progression. Continued innovation and standardization of organoid technology are crucial for advancing precision medicine for biliary diseases and cancer.

01 Feb 2025·International Journal of Cardiology

Handgrip strength as a marker of frailty in patients with transcatheter edge-to-edge repair: Insights from the OCEAN-mitral registry

Article

Author: Takamisawa, Itaru ; Yamamoto, Masanori ; Ikeda, Takanori ; Kodama, Kazuhisa ; Hachinohe, Daisuke ; Yamaguchi, Junichi ; Shirai, Shinichi ; Higuchi, Ryosuke ; Mizutani, Kazuki ; Yamawaki, Masahiro ; Kubo, Shunsuke ; Izumo, Masaki ; Ueno, Hiroshi ; Watanabe, Yusuke ; Isobe, Mitsuaki ; Enta, Yusuke ; Nanasato, Mamoru ; Mizuno, Shingo ; Izumi, Yuki ; Otsuka, Toshiaki ; Bota, Hiroki ; Hayashida, Kentaro ; Amaki, Makoto ; Naganuma, Toru ; Saji, Mike ; Ohno, Yohei ; Iwakura, Tomohiro ; Asami, Masahiko

BACKGROUNDThis study aims to investigate whether handgrip strength can predict all-cause mortality following transcatheter edge-to-edge repair (TEER), and whether it improves after TEER.METHODSThe OCEAN-Mitral Registry includes 2077 patients who had handgrip strength test before TEER. Scores were divided into quartiles according to the handgrip strength. Additionally, 371 of them had follow-up handgrip strength test 1 year after TEER.RESULTSQuartile 4 (weakest) were more likely to be older, smaller, and more symptomatic due to heart failure than others as baseline characteristics. Multivariate analyses revealed that quartile 3 and 4 were independently associated with increased risk of all-cause mortality after TEER compared with quartile 1 as a referent (adjusted hazard ratio 1.58, 95 % confidence interval 1.06-2.35, p = 0.024 for quartile 3, and adjusted hazard ratio 2.40, 95 % confidence interval 1.62-3.55, P < 0.001 for quartile 4). In subanalysis, in primary MR, handgrip strength did not change in patients with successful MR reduction (MR ≤2+), whereas it significantly decreased in those without successful MR reduction (MR 3+/4+). Conversely, in secondary MR, it significantly increased in those with successful MR reduction, whereas it did not change in those without successful MR reduction.CONCLUSIONSWeaker handgrip strength, one of the good indicators of frailty was associated with all-cause mortality following TEER. Reduction in MR was linked to improvements in frailty. This is the largest and the very first study showing that MR reduction ≤2+ after TEER would be important for improving frailty and keeping their resilience in this population.CONDENSED ABSTRACTThe handgrip strength test is a quick and inexpensive way to assess the weakness as a part of frailty. The OCEAN-Mitral Registry includes 2077 patients who had handgrip strength test before transcatheter edge-to-edge repair. Weaker handgrip strength was independently associated with all-cause mortality following TEER. Itis useful for predicting mortality because of its ease. Additionally, we saw the change in frailty assessed by handgrip strength after TEER, and therefore MR reduction ≤2+ after TEER would be important for improving frailty or keeping their resilience in this population.CLINICAL TRIALSOCEAN-Mitral registry (UMIN-ID: UMIN000023653).

01 Feb 2025·Annals of Surgery

Long-term Survival and Functional Outcomes of Laparoscopic Surgery for Clinical Stage I Ultra-low Rectal Cancers Located Within 5 cm of the Anal Verge

Article

Author: Ando, Koji ; Kuriu, Yoshiaki ; Hirano, Yasumitsu ; Tanaka, Keitaro ; Otsuka, Koki ; Hamada, Madoka ; Watanabe, Jun ; Matsuhashi, Nobuhisa ; Yoshimitsu, Masanori ; Yoshioka, Shinichi ; Horie, Hisanaga ; Toiyama, Yuji ; Hamamoto, Hiroki ; Yamaguchi, Shigeki ; Tsukada, Yuichiro ; Maruyama, Satoshi ; Fukunaga, Yosuke ; Ueda, Kazuki ; Hayama, Tamuro ; Nagai, Shuntaro ; Naitoh, Takeshi ; Inoue, Yusuke ; Ohnuma, Shinobu ; Ito, Masaaki ; Suzuki, Motoko ; Sakamoto, Kazuhiro ; Watanabe, Masahiko

Objective:To clarify the long-term oncological outcomes and postoperative anal, urinary, and sexual functions after laparoscopic surgery for clinical stage I very low rectal carcinoma located near the anal canal.Background:Laparoscopic surgery is widely applied for rectal cancer; however, concerns remain, with some studies showing poorer outcomes compared with open surgery.Methods:This single-arm, phase II trial included patients registered preoperatively from 47 institutions in Japan. The planned sample size was 300. The primary end point was the 3-year local recurrence rate. Anal, urinary, and sexual functions were evaluated using a prospective questionnaire.Results:Three hundred patients were registered between January 2014 and March 2017. Anus-preserving surgery was performed in 278 (93%), including 172 who underwent intersphincteric resection (58%) and 106 (36%) who underwent low anterior resection. The 3-year cumulative local recurrence rate was 6.3%. At 3 years postoperatively, 87% of patients used their own anus, and the median incontinence score improved from 12 at 3 months to 8 at 3 years. Only 5% of patients had severe incontinence (incontinence score of 16 points). Postoperative urinary function evaluation showed that the International Prostate Symptom Score and Overactive Bladder Symptom Score decreased 1 week after surgery but recovered to preoperative level 1 month after surgery. International Consultation on Incontinence Questionnaire-Sort Form remained almost stable after surgery. Sexual function evaluation using the International Index of Erectile Function-5 and International Index of Erectile Function-15 revealed that the patients had deteriorated 3 months after surgery but had recovered only slightly by 6 months.Conclusions:Laparoscopic surgery achieves feasible long-term oncological outcomes and a high rate of anus preservation with moderate anal function and an acceptable incontinence score. While urinary function recovered rapidly, sexual function showed poor recovery.

100 Deals associated with Kindai University Faculty of Medicine

100 Translational Medicine associated with Kindai University Faculty of Medicine

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 21 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ONO-8809 ( TBXA2R )	Stroke More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis